02-16-2019 11:26 AM CET - Business, Economy, Finances, Banking & Insurance
Print

Rivaroxaban Market - Global Outlook 2026 By TWO KEY Players Janssen Pharmaceuticals Inc. and Bayer AG

Press release from: Coherent Market Insights
Rivaroxaban Market
Rivaroxaban Market
Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc.

Xarelto is among the most popular anticoagulants, which includes brands like Caumadin, Praxada, and Eliquis. The trajectory growth of rivaroxaban market can be attributed to increasing clinical trials by companies and universities to expand the indication of the drug or to use in combination with other drug.

Get Request Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/1962

For instance, the University Hospital Inselspital, Berne, in collaboration with Bayer and Janssen, and two others, are studying the efficacy of rivaroxaban in patients undergoing bariatric surgery and as on May 2018, the trial was under phase II.

Market players strategize to strengthen their foot hold in the market in spite of high cost by implementing cost-effective treatment schemes. For instance, Janssen Pharmaceuticals offer Xarelto manufacturer coupon or patient assistance program to lower the cost of the drug.

The market players of rivaroxaban market are also concentrating on enhancing effectiveness and reducing the side effects such as bleeding of the drug. For instance, as of June 2018, Janssen Scientific Affairs, LLC is studying the effectiveness of Xarelto with a mobile adherence platform, to improve medication adherence in patients with atrial fibrillation.

However, the presence of cheaper alternative drugs such as warfarin, apixaban, and dabigatran are expected to be major factors hindering the rivaroxaban market growth. The treatment cost using warfarin is as low as US$ 4 per month whereas the cost of rivaroxaban is around US$ 450 per month. This vast difference in cost of the drug lead the patients towards adopting cheaper alternative, thereby negatively affecting the market growth.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/1962

Detailed Segmentation:

Global Rivaroxaban Market, By Strength:
10 mg
15 mg
20 mg
Global Rivaroxaban Market, By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
Global Rivaroxaban Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.
News-ID: 1593759 • Views: 730
More releasesMore releases

You can edit or delete your press release here: